Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 3
2016 1
2017 1
2019 4
2020 3
2021 4
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of the feline atopic syndrome - a systematic review.
Mueller RS, Nuttall T, Prost C, Schulz B, Bizikova P. Mueller RS, et al. Vet Dermatol. 2021 Feb;32(1):43-e8. doi: 10.1111/vde.12933. Vet Dermatol. 2021. PMID: 33470011 Review.
CONCLUSION AND CLINICAL RELEVANCE: In this review, there was good evidence for the efficacy of systemic glucocorticoids and ciclosporin, and limited evidence for the efficacy of topical glucocorticoids, oclacitinib and allergen-specific immunotherapy in feline atopi …
CONCLUSION AND CLINICAL RELEVANCE: In this review, there was good evidence for the efficacy of systemic glucocorticoids and ciclosporin, and …
Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats.
Ortalda C, Noli C, Colombo S, Borio S. Ortalda C, et al. Vet Dermatol. 2015 Aug;26(4):235-e52. doi: 10.1111/vde.12218. Epub 2015 May 4. Vet Dermatol. 2015. PMID: 25940959
HYPOTHESIS/OBJECTIVES: To evaluate the efficacy, ease of administration and tolerability of oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis. ...Owners assessed global efficacy, ease of administration and tolerability with a four-point sca …
HYPOTHESIS/OBJECTIVES: To evaluate the efficacy, ease of administration and tolerability of oclacitinib in feline nonflea-, no …
A pharmacokinetic study of oclacitinib maleate in six cats.
Ferrer L, Carrasco I, Cristòfol C, Puigdemont A. Ferrer L, et al. Vet Dermatol. 2020 Apr;31(2):134-137. doi: 10.1111/vde.12819. Epub 2019 Nov 26. Vet Dermatol. 2020. PMID: 31769185
Its use in cats has been limited by the absence of pharmacokinetic data. OBJECTIVE: To determine the pharmacokinetic parameters of oclacitinib in cats after oral and intravenous administration. ANIMALS: Six adult domestic short hair cats. METHODS AND M …
Its use in cats has been limited by the absence of pharmacokinetic data. OBJECTIVE: To determine the pharmacokinetic parameters of …
An update on the treatment of canine atopic dermatitis.
Saridomichelakis MN, Olivry T. Saridomichelakis MN, et al. Vet J. 2016 Jan;207:29-37. doi: 10.1016/j.tvjl.2015.09.016. Epub 2015 Sep 16. Vet J. 2016. PMID: 26586215 Review.
Symptomatic treatment includes use of glucocorticoids (systemically or topically), ciclosporin and oclacitinib. Other treatment modalities of lower or less proven efficacy include antihistamines, dextromethorphan, fatty acids, feline interferon-omega, misoprostol, p …
Symptomatic treatment includes use of glucocorticoids (systemically or topically), ciclosporin and oclacitinib. Other treatment modal …
Fatal disseminated toxoplasmosis in a feline immunodeficiency virus-positive cat receiving oclacitinib for feline atopic skin syndrome.
Moore A, Burrows AK, Malik R, Ghubash RM, Last RD, Remaj B. Moore A, et al. Vet Dermatol. 2022 Oct;33(5):435-439. doi: 10.1111/vde.13097. Epub 2022 May 29. Vet Dermatol. 2022. PMID: 35644925 Free PMC article.
Immunocompromised individuals are susceptible to recrudescent toxoplasmosis. This case describes a 6-year-old, feline immunodeficiency virus-positive domestic short hair cat with feline atopic skin syndrome that developed fatal toxoplasmosis after treatment w …
Immunocompromised individuals are susceptible to recrudescent toxoplasmosis. This case describes a 6-year-old, feline immunodeficienc …
Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response.
Carrasco I, Ferrer L, Puigdemont A. Carrasco I, et al. J Feline Med Surg. 2022 Aug;24(8):787-793. doi: 10.1177/1098612X211048458. Epub 2021 Oct 6. J Feline Med Surg. 2022. PMID: 34612749
OBJECTIVES: The aim of this study was to assess the efficacy of a new therapeutic regimen of oclacitinib for the control of feline atopic skin syndrome (FASS) and to correlate plasma levels of this drug with clinical effects. METHODS: Twenty-eight client-owned ca …
OBJECTIVES: The aim of this study was to assess the efficacy of a new therapeutic regimen of oclacitinib for the control of feline …
A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats.
Lopes NL, Campos DR, Machado MA, Alves MSR, de Souza MSG, da Veiga CCP, Merlo A, Scott FB, Fernandes JI. Lopes NL, et al. BMC Vet Res. 2019 May 8;15(1):137. doi: 10.1186/s12917-019-1893-x. BMC Vet Res. 2019. PMID: 31068210 Free PMC article.
Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to evaluate the safety and clinical effects of oral oclacitinib maleate in healthy cats. .. …
Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this …
A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis.
Noli C, Matricoti I, Schievano C. Noli C, et al. Vet Dermatol. 2019 Apr;30(2):110-e30. doi: 10.1111/vde.12720. Epub 2019 Jan 17. Vet Dermatol. 2019. PMID: 30656750
BACKGROUND: Oclacitinib is a Janus-kinase inhibitor that decreases interleukin-31-induced pruritus in cats. ...ANIMALS: Forty cats with NFNFIHD. METHODS AND MATERIALS: Cats were randomly assigned to receive oclacitinib (group A, 20 cats, …
BACKGROUND: Oclacitinib is a Janus-kinase inhibitor that decreases interleukin-31-induced pruritus in cats. ...ANIMALS: Forty …
TREATMENT SUCCESS IN THREE ANDEAN BEARS (TREMARCTOS ORNATUS) WITH ALOPECIA SYNDROME USING OCLACITINIB MALEATE (APOQUEL).
Drake GJ, Nuttall T, López J, Magnone W, Leclerc A, Potier R, Lécu A, Guézénec M, Kolter L, Nicolau A, Lemberger K, Pin D, Cosgrove SB. Drake GJ, et al. J Zoo Wildl Med. 2017 Sep;48(3):818-828. doi: 10.1638/2016-0239.1. J Zoo Wildl Med. 2017. PMID: 28920784
ABAS is usually an intractable condition, and, to our knowledge, oclacitinib is the first treatment shown to result in sustained clinical improvement. Further studies on the etiology of ABAS, and on efficacy and long-term safety of oclacitinib are needed....
ABAS is usually an intractable condition, and, to our knowledge, oclacitinib is the first treatment shown to result in sustained clin …
The usefulness of a hydrolysed fish and rice starch elimination diet for the diagnosis of adverse food reactions in cats: an open clinical trial.
Noli C, Beltrando G. Noli C, et al. Vet Dermatol. 2021 Aug;32(4):326-e90. doi: 10.1111/vde.12970. Epub 2021 May 25. Vet Dermatol. 2021. PMID: 34033172 Free PMC article.
Short-acting corticosteroids or oclacitinib were permitted during the first six weeks. Cats showing 50% pruritus and/or lesional improvement were separately challenged with their prior diet, fish and rice. ...CONCLUSION AND CLINICAL IMPORTANCE: FUH may be a useful E …
Short-acting corticosteroids or oclacitinib were permitted during the first six weeks. Cats showing 50% pruritus and/or lesion …
16 results